There are additional published articles stating that the mTOR pathway is abnormally activated in most ESCC cells, that high levels of P-mTOR are linked to poor ESCC prognosis, and that it is, therefore, a therapeutic target for ESCC [26, 27]. The gene discussed is MTOR; the disease is esophageal squamous cell carcinoma.